The European Commission announced, at the beginning of year 2018, the launch of a European initiative for the consortium members: Maxibone project. Ten entities from five different countries being France, Spain, Norway, Denmark, and Germany, participated in this project.
Maxibone consists of different clinical and preclinical trials, that aim to validate the efficacy of different biomaterials applied to bone.
Mimetis Biomaterials continues to be part of the preclinical validation project by developing custom-made biomaterials using 3D micro extrusion, a three-dimensional bioprinting technique.
In a clinical trial that is part of this project, two different treatments applied in a maxillofacial case of vertical alveolar ridge augmentation are compared in terms of the efficacy. On one hand, a bone granular biomaterial will be placed together with human stem cells (hMSC) and on the other hand, an autograft will be used.
Mimetis has received a grant of 320,000 euros to carry out this study, which will take place over 4 years, ending in 2021.
The implementation of this ambitious project will contribute to the positioning of Mimetis Biomaterials at the forefront of innovation and development in the field of bioprinting and bone regeneration technologies. The information acquired throughout the study will provide essential data for its transfer to clinical use, therefore changing the current treatment paradigm related to personalized regenerative medicine.
Mimetis thanks the support of the European Commission for the grant obtained via the Maxibone project (H2020-SC1-2017-Single-Stage-RTD; 779322).